Vanda Pharmaceuticals Inc expected to post a loss of 59 cents a share - Earnings Preview

Vanda Pharmaceuticals

03/08/2026 22:15

Vanda Pharmaceuticals Inc VNDA.OQ VNDA.O is expected to  show a rise in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Washington Washington Dc-based  company is expected to report a 17.8% increase in revenue to $61.925 million from $52.59 million a year ago, according to the mean estimate from 4 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Vanda Pharmaceuticals Inc is for a loss of 59 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Vanda Pharmaceuticals Inc is $14.00, about 174.5% above its last closing price of $5.10
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.65
-0.69
-0.82
Missed
-19.2
Dec. 31 2026
-2.18
-1.32
-0.46
Beat
65.3
Sep. 30 2025
-0.46
-0.45
-0.38
Beat
16.2​
Jun. 30 2025
-0.36
-0.36
-0.46
Missed
-29
​​Mar. 31 2025
-0.60
-0.60
-0.50
Beat
16.2
Dec. 31 2024
-0.11
-0.11
-0.08
Beat
25​
Sep. 30 2024
-0.16
-0.16
-0.09
Beat
44.9
Jun. 30 2024
-0.21
-0.21
-0.08
Beat
61.9
This summary was machine generated August 3 at 21:15 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)